Live Breaking News & Updates on Actuate Therapeutics

Stay updated with breaking news from Actuate therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Actuate Therapeutics Announces Primary Endpoint Met In Phase 2 Study In Pancreatic Cancer

CHICAGO, IL and FORT WORTH, TX (PRWEB) October 28, 2021 Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced ....

United States , Northwestern University , Anwaar Saeed , Devalingam Mahalingam , Benedito Carneiro , Daniel Schmitt , Actuate Therapeutics Inc , University Of Kansas Cancer Center , Brown University , Kansas Cancer , Fast Track Status , Actuate Therapeutics , Press Release ,

Bone Metastasis in Solid Tumors Therapeutics Market Size Anticipated to Observe Growth at a Steady Rate of 2.24% for the Study Period 2018-30, Estimates DelveInsight

/PRNewswire/ DelveInsight s Bone Metastasis in Solid Tumors Market Insights report proffers a detailed comprehension of Bone Metastasis in Solid Tumors. ....

United States , Yong Shun , United Kingdom , Dong Co , Shruti Thakur , Schick Sirona , Noveome Biotherapeutics , Prnewswire Delveinsight , Dompe Farmaceutici , Sonova Holding , Cochlear Ltd , Donga St Co Ltd , Chia Tai Tianqing Pharmaceutical Group Co Ltd , William Demant Holding Bernafon , Progenics Pharmaceuticals , Sonic Innovations Inc , Arena Pharmaceuticals , Natus Medical Incorporated , Eyevance Pharmaceuticals , Osteosys Co , Hologic Inc , Mirum Pharmaceuticals , Yong Shun Technology Development , Qilu Pharmaceuticals Co Ltd , Cq Biomed Inc , Shanghai Jmt Bio Inc ,

Actuate Therapeutics Announces FDA Fast Track Designation for 9-ING-41 for Treatment of Pancreatic Cancer

Actuate Therapeutics Announces FDA Fast Track Designation for 9-ING-41 for Treatment of Pancreatic Cancer
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.

United States , Francis Giles , Daniel Schmitt , Actuate Therapeutics Inc , Drug Administration , Brown University , Dana Farber Cancer Institute , Fast Track Designation , Chief Medical , Adultt Cell , Actuate Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , பிரான்சிஸ் கில்ஸ் , டேனியல் ஶ்மிட் , பழுப்பு பல்கலைக்கழகம் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , வேகமாக டிராக் பதவி , தலைமை மருத்துவ ,

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

About Actuate Therapeutics
Actuate Therapeutics, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. For additional information, please visit the company s website at http://www.actuatetherapeutics.com.
About Lantern Pharma
Lantern Pharma (Nasdaq: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR
® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across seven disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern s approach represents the potential to deliver best-in-class outco ....

United States , Marek Ciszewski , Jayson Parker , Daniel Schmitt , University Of Toronto , Lantern Pharma Inc , Exchange Commission On , Actuate Therapeutics Inc , Securities Exchange , Lantern Pharma , Chief Executive Officer , Actuate Therapeutics , Cancer Medicine , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission , Antern Pharma And Actuate Therapeutics Announce Research Amp Development Collaboration Leveraging Lantern 39s Artificial Intelligence Platform , ஒன்றுபட்டது மாநிலங்களில் , ஜெய்சன் பார்க்கர் , டேனியல் ஶ்மிட் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , விளக்கு பார்மா இன்க் , பரிமாற்றம் தரகு ஆன் , பத்திரங்கள் பரிமாற்றம் ,

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
- RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes
- Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during third quarter of 2021
- Expanded potential indications for LP-184 to include ATRT pediatric brain cancers
- Initiated preclinical development of new molecular entity, LP-284, in hematologic cancers
- Strengthened intellectual property portfolio with filing of over 10 patent applications
- Launched research and development collaboration leveraging RADR® for accelerating drug development for Actuate Therapeutics GSK3β drug candidate ....

United States , Marek Ciszewski , Lantern Pharma Inc , Exchange Commission On , Prnewswire Lantern Pharma Inc , Securities Exchange , Panna Sharma , Actuate Therapeutics , Non Small Cell Lung Cancer , Drug Conjugate , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission , Par Value , Consolidated Statements , ஒன்றுபட்டது மாநிலங்களில் , விளக்கு பார்மா இன்க் , பரிமாற்றம் தரகு ஆன் , பத்திரங்கள் பரிமாற்றம் , பன்னா ஷர்மா , அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் , பத்திரங்கள் நாடகம் , பத்திரங்கள் பரிமாற்றம் நாடகம் , ஆபத்து காரணிகள் ,